ConductScience.org, home

Comparison · NCT03715153-0e5cddd6

BUMETANIDE (S95008) vs PLACEBO: Number of Patients With Abnormalities in 12-leads Electrocardiogram (ECG) Parameters

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. BUMETANIDE (S95008) vs PLACEBO: Number of Patients With Abnormalities in 12-leads Electrocardiogram (ECG) Parameters. Trial comparisons, record NCT03715153-0e5cddd6. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03715153-0e5cddd6

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.0469wilson
Risk in group 2000.0475wilson
Risk difference, group 1 minus group 20-0.04750.0469newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treatfrom the risk difference intervalthe two groups' risks are equal

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1BUMETANIDE (S95008)BUMETANIDE/S95008: Oral solution dosed at 0.5 mg/mL Taken twice daily.078OG000
Group 2PLACEBOPLACEBO: Oral solution Taken twice daily.077OG001

Outcome

Type
SECONDARY
Title
Number of Patients With Abnormalities in 12-leads Electrocardiogram (ECG) Parameters
Description
Number of patients with clinically significant ECG abnormalities~The 12-lead electrocardiogram (ECG) is a medical test that is recorded using leads, or nodes, attached to the body. Electrocardiograms (ECGs), capture the electrical activity of the heart and transfer it to graphed paper where abnormalities are reported and interpretated by the cardiologist.
Time frame
Week 26
Population
As this measure was collected through week 26, only data gathered during the double-blind period for arms Bumetanide and Placebo were collected.

Source ClinicalTrials.gov

Trial

Title
Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT number
NCT03715153
Phases
PHASE3
Conditions
Autism Spectrum Disorder (ASD)
Interventions
BUMETANIDE (S95008) for week 0 - 26, PLACEBO for week 0 - 26, Open-Label BUMETANIDE (S95008) for weeks 26 - 52
Lead sponsor
Institut de Recherches Internationales Servier
Results first posted
2023-06-05

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03715153-0e5cddd6